Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice Second Edition by Mikaela Olsen, Elizabeth Prechtel Dunphy, Suzanne Walker, Kristine LeFebvre ISBN 978-1635930559 1635930553
Original price was: $50.00.$35.00Current price is: $35.00.
Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice Second Edition by Mikaela Olsen, Elizabeth Prechtel Dunphy, Suzanne Walker, Kristine LeFebvre- Ebook PDF Instant Download/Delivery: 978-1635930559, 1635930553
Full download Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice Second Edition after payment
Product details:
ISBN 10: 1635930553
ISBN 13: 978-1635930559
Author: Mikaela Olsen, Elizabeth Prechtel Dunphy, Suzanne Walker, Kristine LeFebvre
Oncology nursing is a unique specialty that requires continuous learning to stay current on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and its treatment-related toxicities. The Oncology Nursing Society’s Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Extensive drug tables provide nurses with categorical drug information based on treatment type and tips for managing patients receiving these treatments. New evidence relating to cancer nursing care is incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. Expanded content on genomics corresponds with the progress made toward personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship are also included. A QR code is provided with the purchase of this book, allowing access to periodic drug updates.
Table of contents:
SECTION I. PROFESSIONAL PRACTICE CONSIDERATIONS
Chapter 1. Professional Practice Considerations
A. Scope and standards……
B. Professional education….
C. Policies and procedures.
D. Antineoplastic medication safety.
E. Quality and safety monitoring..
References
Chapter 2. Ethical and Legal Issues
A. Ethical issues
B. Legal issues related to cancer therapy.
References
Chapter 3. Patient Education
A. Patient education overview.
B. Short-term outcomes of patient education
C. Long-term outcomes of patient education
D. Barriers to patient education
E. Methods of patient education.
F. Scope of information.
G. Documentation
References
SECTION II. CANCERAND CANCER TREATMENT
Chapter 4. Overview of Cancer and Cancer Treatment
A. Definition of cancer
B. The Cancer Care Continuum framework.
C. Cancer staging and grading
D. Cancer treatment modalities
E. Treatment approaches.
F. Treatment strategies.
G. Measuring response
H. Factors affecting treatmentresponse
I. Adherence
J. Toxicity grading and documentation
References
Chapter 5. Clinical Trials and Drug Development.
A. Clinical research.
B. Drug and biologic development process.
C. Expanded access
References
SECTION III. CANCERTHERAPEUTICS
Chapter 6. Chemotherapy
A. Chemotherapy in the treatment of cancer
B. Classification of chemotherapy agents
C. Chemotherapy classifications
D. Combination chemotherapy principles.
References
Chapter 7. Hormone Therapy
A. Hormone therapy in the treatment of cancer.
B. Cancers treated with hormone therapy
C. Hormone treatment categories
References
Chapter 8. Targeted Therapy
A. Targeted therapies in the treatment of cancer.
B. Adverse effects of targeted therapies.
C. Drug-drug interactions.
References
Chapter 9. Principles of the Immune System
A. Overview of immunology.
B. Types of immune response.
C. Organs of the immune system
D. Cells of the immune system.
E. Immune system proteins and receptors
F. Phases of immune response…
G. Tumor escape mechanisms..
References
Chapter 10. Immunotherapy
A. Overview
B. Modalities of immunotherapy
C. General patient and family education.
References
SECTION IV. TREATMENT ADMINISTRATION AND SAFETY
Chapter 11. Administration Considerations.
A. Components of safe and effective administration of cancer therapies
B. Pretreatment
C. Chemotherapy, targeted therapy, and immunotherapy dosing
D. Verification
E. Routes of chemotherapy, immunotherapy, and targeted therapy administration
References
Chapter 12. Safe Handling of Hazardous Drugs
A. Safe handling and disposal of hazardous drugs.
B. Definition
C. Antineoplastic drugs.
D. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings…
E. NIOSH List of Hazardous Drugs in Healthcare Settings
F. Immunotherapy.
G. Routes of occupational exposure…
H. Hierarchy of hazard controls.
1. Guidelines for personal protective equipment.
J. Storage and labeling.
K. Safe handling precautions during compounding.
L. Transporting HDs
M. Safe handling precautions during administration. N. Special precautions for radiopharmaceuticals
O. Handling body fluids
P. Handling patient linens.
Q. Disposal of hazardous drugs and materials contaminated with hazardous drugs
R. Procedures following acute hazardous drug exposure.
S. Spill management…
T. Requirements for policies regarding the handling of hazardous drugs
References
Chapter 13. Infusion-Related Complications
A. Complications during or shortly after parenteral administration of cancer treatment.
B. Extravasation of vesicants resulting in potential tissue damage
C. Imitation…
D. Flare reaction…
E. Acute infusion-related reactions.
F. Patient and caregiver education..
References
SECTION V. TREATMENT-RELATED COMPLICATIONS
Chapter 14. Myelosuppression.
A. Overview
B. Types of cytopenias.
References
Chapter 15. Gastrointestinal and Mucosal Toxicities
A. Nausea and vomiting
B. Anorexia and cachexia….
C. Diarrhea.
D. Colitis.
E. Pancreatitis
F. Mucositis
G. Perirectal cellulitis.
H. Constipation
References
Chapter 16. Cardiovascular Toxicities.
A. Overview
B. Conduction pathway disorders.
C. Vascular abnormalities..
D. Venous thromboembolism..
E. Coronary artery disease..
F. Left ventricular dysfunction and heart failure.
G. Myocarditis..
References
Chapter 17. Pulmonary Toxicities
A. Overview…
B. Interstitiallung disease.
C. Diffuse alveolar hemorrhage
D. Acute promyelocytic leukemia treatment-related differentiation syndrome
E. Pleural effusions
F. Patient and family education.
References
Chapter 18. Hepatic Toxicities.
A. Overview…
B. Pathophysiology
C. Incidence…
D. Risk factors.
E. Clinical manifestations.
F. Pathologic manifestations associated with drug toxicity…..
G. Assessment…
H. Collaborative management.
1. Patient and family education..
References
Chapter 19. Genitourinary Toxicities.
A. Overview.
B. Antineoplastic-associated genitourinary toxicities.
C. Drug specific considerations
References
Chapter 20. Altered Sexual and Reproductive Functioning..
A. Alterations in sexual functioning
B. Alterations in reproductive functioning.
References
Chapter 21. Cutaneous Toxicities and Alopecia.
A. Cutaneous toxicity…
B. Alopecia
References
Chapter 22. Endocrine Toxicities.
A. Overview…
B. Drug specific endocrinopathies…
C. Immune checkpoint inhibitor related endocrinopathies
References
Chapter 23. Fatigue.
A. Overview..
B. Pathophysiology.
C. Incidence.
D. Assessment…
E. Collaborative management.
F. Principles of patient and family education and care planning
References
Chapter 24. Neurologic Toxicities
A. Overview.
B. Radiation-induced central nervous system toxicity
C. Radiation-induced peripheral nervous system toxicity
D. Chemotherapy-induced central nervous system toxicity…
E. Peripheral neuropathy…
F. Common antineoplastics conferring increased neurotoxicity
G. Risk factors and prophylaxis…
H. Cognitive impairment…
1. Patient and family education..
References
Chapter 25. Ocular Toxicities.
A. Overview
B. Pathophysiology
C. Incidence…
D. Risk factors
E. Clinical manifestations.
F. Assessment…
G. Collaborative management.
H. Patient and family education..
References
SECTION VI. POST-TREATMENT
Chapter 26. Post-Treatment and Survivorship Care.
A. Overview…
B. Cancer survivorship care.
C. Long-termand late effects of cancer treatment
References
APPENDICES.
INDEX.
People also search for:
chemotherapy and immunotherapy guidelines
ons chemotherapy and immunotherapy guidelines
chemotherapy and immunotherapy guidelines and recommendations for practice pdf
chemotherapy and immunotherapy guidelines and recommendations
can immunotherapy be combined with chemotherapy
Tags: Mikaela Olsen, Elizabeth Prechtel Dunphy, Suzanne Walker, Kristine LeFebvre, Chemotherapy and Immunotherapy, Guidelines and Recommendations